首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >98%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIA |
| Uniprot No | Q16674 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-131aa |
| 氨基酸序列 | GPMPKLADRK LCADQECSHP ISMAVALQDY MAPDCRFLTI HRGQVVYVFS KLKGRGRLFW GGSVQGDYYG DLAARLGYFP SSIVREDQTL KPGKVDVKTD KWDFYCQ |
| 预测分子量 | 12.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIA(黑色素瘤抑制性活性蛋白)重组蛋白的示例参考文献(文献为虚构示例，仅作格式参考)：
---
1. **标题**: *Recombinant Expression and Functional Analysis of Melanoma Inhibitory Activity (MIA) Protein in Bacterial Systems*
**作者**: Schmidt, J. et al.
**摘要**: 研究通过大肠杆菌系统重组表达MIA蛋白，优化纯化工艺并验证其抑制黑色素瘤细胞迁移的生物学活性，为癌症治疗研究提供基础工具。
2. **标题**: *Structural Insights into MIA Protein Interaction with Extracellular Matrix Components*
**作者**: Li, X. & Wagner, R.
**摘要**: 利用X射线晶体学解析MIA重组蛋白的三维结构，揭示其与细胞外基质蛋白(如纤维连接蛋白)结合的分子机制，阐明其在肿瘤转移中的作用。
3. **标题**: *MIA Recombinant Protein Attenuates Cartilage Degeneration in Osteoarthritis Models*
**作者**: Park, S. et al.
**摘要**: 在哺乳动物细胞中表达MIA重组蛋白，通过动物模型证明其通过调控软骨细胞凋亡减缓骨关节炎进展，提示其潜在治疗应用。
4. **标题**: *Development of a High-Yield MIA Fusion Protein for Targeted Drug Delivery*
**作者**: Gupta, A. et al.
**摘要**: 设计并表达MIA与荧光标记的融合蛋白，验证其靶向肿瘤细胞的能力，为基于MIA的药物递送系统开发提供新策略。
---
如需真实文献，建议通过 **PubMed** 或 **Google Scholar** 检索关键词：`"MIA recombinant protein"`, `"Melanoma Inhibitory Activity expression"`, `"MIA protein function"`。
**Background of MIA Recombinant Protein**
The **Melanoma Inhibitory Activity (MIA)** protein, first identified in the 1990s, is a small, secreted protein initially discovered for its role in inhibiting melanoma cell proliferation. Structurally, MIA belongs to the S100 family of calcium-binding proteins and is characterized by a unique SH3 domain-like fold. It is predominantly expressed in malignant melanoma tissues and chondrocytes, playing a dual role in tumor progression and cartilage homeostasis.
MIA's functional significance lies in its interaction with extracellular matrix (ECM) components, such as integrins and fibronectin, which modulate cell adhesion, migration, and metastasis. In melanoma, MIA promotes tumor invasion by disrupting cell-ECM interactions, facilitating immune evasion, and enhancing metastatic potential. Conversely, in cartilage, MIA supports chondrocyte survival and matrix maintenance, with dysregulation linked to osteoarthritis.
**Recombinant MIA protein** is produced using genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and post-translational modifications. This engineered protein retains the biological activity of native MIA, enabling its use in *in vitro* and *in vivo* studies. Researchers employ recombinant MIA to investigate its signaling pathways, evaluate therapeutic targets, and develop diagnostic tools for melanoma or cartilage-related diseases.
The development of MIA recombinant protein has also spurred interest in antibody production and drug discovery. Inhibitors targeting MIA are being explored to block melanoma metastasis, while its cartilage-protective properties are studied for regenerative therapies. Despite progress, challenges remain in understanding its context-dependent roles and optimizing clinical applications. Overall, MIA recombinant protein serves as a critical tool in oncology and musculoskeletal research, bridging molecular insights to therapeutic innovation.
×
